Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

507
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
507
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

266
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
266
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.3K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

247
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
247
Clinical Trials01:16

Clinical Trials

7.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diabetes Technologist: Optimal Use of Technology in Everyday Practice.

Journal of diabetes science and technology·2026
Same author

Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.

Lancet (London, England)·2026
Same author

Diabetes Mellitus and the Heart.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2026
Same author

Smart Pens: Expectations Regarding Use and Functionality From Health Care Providers.

Journal of diabetes science and technology·2026
Same author

Body Mass Index and All-Cause, Cancer, and Cardiovascular Mortality in Adults Aged 16-50 Years With and Without Type 2 Diabetes: An Analysis of Primary Care Records in England.

Diabetes, obesity & metabolism·2026
Same author

Diabetes Technology Across the Lifespan of People With Diabetes (Ages 2-88 Years): Insights From the dt-Report on Usage Trends Across all Age Groups.

Journal of diabetes science and technology·2026

Related Experiment Video

Updated: Sep 5, 2025

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

7.6K

Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials.

Lutz Heinemann1, Melanie Davies2, Philip Home3

  • 1Science Consulting in Diabetes GmbH, Kaarst, Deutschland.

Journal of Diabetes Science and Technology
|July 12, 2022
PubMed
Summary

Biosimilar insulins, highly similar versions of existing products, are emerging due to patent expirations. Increased awareness and confidence in these affordable alternatives can expand global access to insulin therapy.

Keywords:
biologicsbiosimilarclampclinical trialsdiabetesinsulininsulin therapymanufacturepharmacodynamicpharmacokineticregulation

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.4K

Related Experiment Videos

Last Updated: Sep 5, 2025

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

7.6K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.4K

Area of Science:

  • Biotechnology and Pharmaceutical Sciences
  • Regulatory Science

Background:

  • Expiring patents for first-generation insulin analogues enable the market entry of biosimilar insulins, which are highly similar biological products.
  • Biosimilars, derived from complex biologics, are not exact copies but demonstrate significant functional and structural similarity to reference products.
  • Establishing biosimilarity involves rigorous analytical, preclinical, and clinical assessments, adhering to strict regulatory guidelines from agencies like the FDA and EMA.

Purpose of the Study:

  • To enhance clinical understanding of the stringent development, manufacturing, and regulatory standards governing biosimilar insulins.
  • To provide insights into the evidence base required for biosimilar insulin approval.

Main Methods:

  • A review of recent studies indexed in PubMed.
  • Inclusion of relevant regulatory documents from major health authorities.

Main Results:

  • The emergence of biosimilar insulins, driven by price competition, has the potential to broaden worldwide access to insulin analogues.
  • Healthcare professionals and patients need increased awareness and confidence to fully leverage the cost benefits of biosimilar insulins.

Conclusions:

  • Biosimilar insulins offer a pathway to increased global access to diabetes management tools.
  • Building confidence among stakeholders is crucial for maximizing the impact of biosimilar insulin adoption and its associated cost reductions.